1094P NeoRisk: Neoadjuvant immunotherapy (NeoIT) recurrence risk assessment tool

I. Pires da Silva; P. Grover; Nurudeen A. Adegoke; R. Rawson; Nigel Maher; Andrew J. Colebatch; Jordan W. Conway; M.S. Carlino; Serigne Lo; A.M. Menzies; Richard A Scolyer; G.V. Long

doi:10.1016/j.annonc.2024.08.1162

Related publications

Article2024

Neoadjuvant immunotherapy (neoIT) in melanoma: A prediction tool for pathological response and recurrence, and the role of adjuvant (Adj) therapy (Tx) to improve recurrence-free survival (RFS).

Ines Esteves Domingues Pires Da Silva, Piyush Grover, Nurudeen A. Adegoke, Robert V. Rawson, Andrew J. Colebatch, Matteo S. Carlino, Serigne Lo, Alexander M. Menzies, Richard A Scolyer, Georgina V. Long

Article2024

Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy

Wei Yen Chan, Jenny Lee, Ashleigh Stewart, Russell J. Diefenbach, Maria Gonzalez, Alexander M. Menzies, Christian U. Blank, Richard A Scolyer, Georgina V. Long, Helen Rizos

Article2025

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Andrea Boutros, Amelia M. Taylor, Isabel Li, Nurudeen A. Adegoke, Terence Z. Wong, Alexander H. R. Varey, Kerwin F. Shannon, Sydney Ch'ng, R.P.M. Saw, Thomas E. Pennington, Jonathan R. Stretch, Andrew J. Spillane, Alexander C.J. van Akkooi, Richard A Scolyer, Inês Pires da Silva, Matteo S. Carlino, Georgina V. Long, Serigne Lo, Alexander M Menzies

Article2022

850P A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

A.M. Taylor, C. Galea, Alexander Hr Varey, Kerwin F. Shannon, S. Ch'ng, R.P.M. Saw, T.E. Pennington, J. Stretch, Andrew J. Spillane, Alexander C.J. van Akkooi, I. Pires da Silva, M.S. Carlino, Richard A Scolyer, G.V. Long, Serigne Lo, A.M. Menzies

Article2023

Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now

Georgina V. Long, Alexander M. Menzies, Richard A Scolyer